Cargando…

Community pharmacists’ acceptance of prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)

BACKGROUND: Pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) prevention is highly effective. Pharmacists can increase PrEP accessibility through pharmacist prescribing. This study aimed to determine pharmacists’ acceptance of a pharmacist PrEP prescribing service in Nova Scotia...

Descripción completa

Detalles Bibliográficos
Autores principales: Booker, Connor, Murphy, Andrea L, Isenor, Jennifer E., Ramsey, Tasha D., Smith, Alesha J., Bishop, Andrea, Kelly, Deborah V., Woodill, Lisa, Richard, Greg, John Wilby, Kyle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186867/
https://www.ncbi.nlm.nih.gov/pubmed/37201164
http://dx.doi.org/10.1177/17151635231152218
_version_ 1785042638915764224
author Booker, Connor
Murphy, Andrea L
Isenor, Jennifer E.
Ramsey, Tasha D.
Smith, Alesha J.
Bishop, Andrea
Kelly, Deborah V.
Woodill, Lisa
Richard, Greg
John Wilby, Kyle
author_facet Booker, Connor
Murphy, Andrea L
Isenor, Jennifer E.
Ramsey, Tasha D.
Smith, Alesha J.
Bishop, Andrea
Kelly, Deborah V.
Woodill, Lisa
Richard, Greg
John Wilby, Kyle
author_sort Booker, Connor
collection PubMed
description BACKGROUND: Pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) prevention is highly effective. Pharmacists can increase PrEP accessibility through pharmacist prescribing. This study aimed to determine pharmacists’ acceptance of a pharmacist PrEP prescribing service in Nova Scotia. METHODS: A triangulation mixed methods study consisting of an online survey and qualitative interviews was conducted with Nova Scotia community pharmacists. The survey questionnaire and qualitative interview guide were underpinned by the 7 constructs of the Theoretical Framework of Acceptability (affective attitude, burden, ethicality, opportunity costs, intervention coherence, perceived effectiveness and self-efficacy). Survey data were analyzed descriptively and with ordinal logistic regression to determine associations between variables. Interview transcripts were deductively coded according to the same constructs and then inductively coded to identify themes within each construct. RESULTS: A total of 214 community pharmacists completed the survey, and 19 completed the interview. Pharmacists were positive about PrEP prescribing in the constructs of affective attitude (improved access), ethicality (benefits communities), intervention coherence (practice alignment) and self-efficacy (role). Pharmacists expressed concerns about burden (increased workload), opportunity costs (time to provide the service) and perceived effectiveness (education/training, public awareness, laboratory test ordering and reimbursement). CONCLUSION: A PrEP prescribing service has mixed acceptability to Nova Scotia pharmacists yet represents a model of service delivery to increase PrEP access to underserved populations. Future service development must consider pharmacists’ workload, education and training as well as factors relating to laboratory test ordering and reimbursement.
format Online
Article
Text
id pubmed-10186867
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-101868672023-05-17 Community pharmacists’ acceptance of prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) Booker, Connor Murphy, Andrea L Isenor, Jennifer E. Ramsey, Tasha D. Smith, Alesha J. Bishop, Andrea Kelly, Deborah V. Woodill, Lisa Richard, Greg John Wilby, Kyle Can Pharm J (Ott) Research and Clinical BACKGROUND: Pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) prevention is highly effective. Pharmacists can increase PrEP accessibility through pharmacist prescribing. This study aimed to determine pharmacists’ acceptance of a pharmacist PrEP prescribing service in Nova Scotia. METHODS: A triangulation mixed methods study consisting of an online survey and qualitative interviews was conducted with Nova Scotia community pharmacists. The survey questionnaire and qualitative interview guide were underpinned by the 7 constructs of the Theoretical Framework of Acceptability (affective attitude, burden, ethicality, opportunity costs, intervention coherence, perceived effectiveness and self-efficacy). Survey data were analyzed descriptively and with ordinal logistic regression to determine associations between variables. Interview transcripts were deductively coded according to the same constructs and then inductively coded to identify themes within each construct. RESULTS: A total of 214 community pharmacists completed the survey, and 19 completed the interview. Pharmacists were positive about PrEP prescribing in the constructs of affective attitude (improved access), ethicality (benefits communities), intervention coherence (practice alignment) and self-efficacy (role). Pharmacists expressed concerns about burden (increased workload), opportunity costs (time to provide the service) and perceived effectiveness (education/training, public awareness, laboratory test ordering and reimbursement). CONCLUSION: A PrEP prescribing service has mixed acceptability to Nova Scotia pharmacists yet represents a model of service delivery to increase PrEP access to underserved populations. Future service development must consider pharmacists’ workload, education and training as well as factors relating to laboratory test ordering and reimbursement. SAGE Publications 2023-02-28 /pmc/articles/PMC10186867/ /pubmed/37201164 http://dx.doi.org/10.1177/17151635231152218 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research and Clinical
Booker, Connor
Murphy, Andrea L
Isenor, Jennifer E.
Ramsey, Tasha D.
Smith, Alesha J.
Bishop, Andrea
Kelly, Deborah V.
Woodill, Lisa
Richard, Greg
John Wilby, Kyle
Community pharmacists’ acceptance of prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
title Community pharmacists’ acceptance of prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
title_full Community pharmacists’ acceptance of prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
title_fullStr Community pharmacists’ acceptance of prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
title_full_unstemmed Community pharmacists’ acceptance of prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
title_short Community pharmacists’ acceptance of prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
title_sort community pharmacists’ acceptance of prescribing pre-exposure prophylaxis (prep) for human immunodeficiency virus (hiv)
topic Research and Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186867/
https://www.ncbi.nlm.nih.gov/pubmed/37201164
http://dx.doi.org/10.1177/17151635231152218
work_keys_str_mv AT bookerconnor communitypharmacistsacceptanceofprescribingpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT murphyandreal communitypharmacistsacceptanceofprescribingpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT isenorjennifere communitypharmacistsacceptanceofprescribingpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT ramseytashad communitypharmacistsacceptanceofprescribingpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT smithaleshaj communitypharmacistsacceptanceofprescribingpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT bishopandrea communitypharmacistsacceptanceofprescribingpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT kellydeborahv communitypharmacistsacceptanceofprescribingpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT woodilllisa communitypharmacistsacceptanceofprescribingpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT richardgreg communitypharmacistsacceptanceofprescribingpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv
AT johnwilbykyle communitypharmacistsacceptanceofprescribingpreexposureprophylaxisprepforhumanimmunodeficiencyvirushiv